Clinical Trials Browser

Phase 2 × INDUSTRY × trastuzumab deruxtecan × Clear all

NCT07069712 2026-03-10

A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

Phase 2 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT04379596 2026-02-23

DG-03

Phase 2 Recruiting

Gastrointestinal

Adenocarcinoma, Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT04482309 2026-01-21

DPT02

Phase 2 Recruiting

468 enrolled 1 FDA

Gastrointestinal

Pancreatic Neoplasms, Colorectal Neoplasms

NCT04744831 2026-01-14

DESTINY-CRC02

Phase 2 Completed

122 enrolled 21 charts 1 FDA

Gastrointestinal

Colorectal Neoplasms

NCT04644237 2025-11-21

DESTINY-LUNG02

Phase 2 Completed

152 enrolled 22 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT03334617 2025-10-27

HUDSON

Phase 2 Active not recruiting

528 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung

NCT06271837 2025-10-22

A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors

Phase 2 Recruiting

Breast Neoplasms

NCT04639219 2025-10-16

DPT01

Phase 2 Active not recruiting

102 enrolled 18 charts

Neoplasm Metastasis

NCT04539938 2025-09-30

HER2CLIMB-04

Phase 2 Completed

70 enrolled 11 charts

Breast Neoplasms

NCT05246514 2025-08-28

DL-05

Phase 2 Active not recruiting

72 enrolled 16 charts

HER2-mutant Non-Small Cell Lung Cancer

NCT03248492 2025-06-26

DESTINY-Breast01

Phase 2 Terminated

253 enrolled 21 charts 1 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT06832202 2025-06-15

A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients

Phase 2 Recruiting

HER2-low Hormone Receptor Positive Breast Cancer

NCT03505710 2025-05-30

DESTINY-Lung01

Phase 2 Terminated

181 enrolled 17 charts 1 FDA

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT04014075 2025-04-03

DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)

Phase 2 Completed

79 enrolled 19 charts

Neoplasm Metastasis

NCT04989816 2024-11-21

DG-06

Phase 2 Completed

95 enrolled 22 charts

Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

NCT03329690 2022-03-18

DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]

Phase 2 Completed

233 enrolled 26 charts 1 FDA

Gastrointestinal

Adenocarcinoma, Gastrointestinal Neoplasms

NCT03384940 2021-10-18

DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)

Phase 2 Completed

86 enrolled 26 charts

Gastrointestinal

Neoplasms, Colorectal Neoplasms